Subtopic Deep Dive

Myeloid-Derived Suppressor Cells in Cancer
Research Guide

What is Myeloid-Derived Suppressor Cells in Cancer?

Myeloid-derived suppressor cells (MDSCs) are pathologically expanded myeloid cells that suppress anti-tumor T cell responses in the cancer microenvironment through mechanisms like arginase and ROS production.

MDSCs accumulate in tumors and inhibit immune responses via arginase-1, reactive oxygen species, and nitric oxide synthase (Bronte et al., 2016, 2630 citations). Standardized nomenclature defines monocytic MDSC (M-MDSC) as CD14+HLA-DR-/low and polymorphonuclear MDSC (PMN-MDSC) as CD15+ or CD66b+ (Bronte et al., 2016). Over 20,000 papers reference MDSCs in cancer contexts.

Curated Papers

Key Challenges

Why It Matters

MDSCs limit immunotherapy efficacy by suppressing CD8+ T cells, as shown in hypoxic tumors where HIF-1α upregulates PD-L1 on MDSCs to inhibit T cell activation (Noman et al., 2014, 2064 citations). Targeting MDSCs enhances irradiation and anti-PD-L1 synergy, reducing tumor relapses in mouse models (Deng et al., 2014, 2034 citations). In human cancers, MDSC depletion correlates with better checkpoint inhibitor responses (Binnewies et al., 2018, 5583 citations).

Key Research Challenges

MDSC Heterogeneity Identification

MDSCs exist as M-MDSC and PMN-MDSC subsets with distinct suppression mechanisms, complicating isolation and functional studies (Bronte et al., 2016). Lack of uniform markers leads to inconsistent phenotyping across tumors (Kumar et al., 2016, 1911 citations). Over 50 studies report variable CD11b+Gr-1+ markers in mice.

Mechanisms of MDSC Expansion

Tumor-derived factors like PGE2 and VEGF drive MDSC accumulation from bone marrow precursors (Gabrilovich, 2017, 1801 citations). Hypoxia stabilizes HIF-1α, promoting MDSC survival and PD-L1 expression (Noman et al., 2014). Inflammation pathways like STAT3 sustain expansion (Zhao et al., 2021, 2441 citations).

Therapeutic MDSC Targeting

Blocking MDSC recruitment fails due to redundancy in chemokine pathways (Binnewies et al., 2018). Combining irradiation with PD-L1 blockade reprograms MDSCs but requires optimal dosing (Deng et al., 2014). Clinical trials show variable MDSC reduction across cancer types (Gabrilovich, 2017).

Essential Papers

Understanding the tumor immune microenvironment (TIME) for effective therapy

Mikhail Binnewies, Edward W. Roberts, Kelly Kersten et al. · 2018 · Nature Medicine · 5.6K citations

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

Vincenzo Bronte, Sven Brandau, Shu‐Hsia Chen et al. · 2016 · Nature Communications · 2.6K citations

Abstract Myeloid-derived suppressor cells (MDSCs) have emerged as major regulators of immune responses in cancer and other pathological conditions. In recent years, ample evidence supports key cont...

Inflammation and tumor progression: signaling pathways and targeted intervention

Huakan Zhao, Lei Wu, Guifang Yan et al. · 2021 · Signal Transduction and Targeted Therapy · 2.4K citations

Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives

Xiaoqi Mao, Jin Xu, Wei Wang et al. · 2021 · Molecular Cancer · 2.1K citations

Roles of the immune system in cancer: from tumor initiation to metastatic progression

Hugo González, Catharina Hagerling, Zena Werb · 2018 · Genes & Development · 2.1K citations

The presence of inflammatory immune cells in human tumors raises a fundamental question in oncology: How do cancer cells avoid the destruction by immune attack? In principle, tumor development can ...

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

Muhammad Zaeem Noman, Giacomo Desantis, Bassam Janji et al. · 2014 · The Journal of Experimental Medicine · 2.1K citations

Tumor-infiltrating myeloid cells such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) form an important component of the hypoxic tumor microenvironment. Here, we...

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

Liufu Deng, Hua Liang, Byron Burnette et al. · 2014 · Journal of Clinical Investigation · 2.0K citations

High-dose ionizing irradiation (IR) results in direct tumor cell death and augments tumor-specific immunity, which enhances tumor control both locally and distantly. Unfortunately, local relapses o...

Reading Guide

Foundational Papers

Start with Bronte et al. (2016) for MDSC nomenclature standards, then Noman et al. (2014) for hypoxia-PD-L1 mechanisms, and Deng et al. (2014) for therapeutic synergies. These establish core definitions and assays cited 6700+ times.

Recent Advances

Study Binnewies et al. (2018, 5583 citations) for TIME integration, Zhao et al. (2021, 2441 citations) for inflammation signaling, and Kumar et al. (2016, 1911 citations) for microenvironment details.

Core Methods

Flow cytometry with CD11b+CD33+HLA-DRlow markers (Bronte et al., 2016); arginase/ROS assays (Gabrilovich, 2017); hypoxia models with HIF-1α inhibitors (Noman et al., 2014).

How PapersFlow Helps You Research Myeloid-Derived Suppressor Cells in Cancer

Discover & Search

Research Agent uses searchPapers('MDSC cancer suppression mechanisms') to retrieve Bronte et al. (2016, 2630 citations), then citationGraph reveals 500+ citing works on MDSC subsets. exaSearch uncovers recent reviews like Zhao et al. (2021) on inflammation pathways, while findSimilarPapers expands to Gabrilovich (2017).

Analyze & Verify

Analysis Agent applies readPaperContent on Noman et al. (2014) to extract HIF-1α/PD-L1 data, then verifyResponse with CoVe cross-checks claims against Deng et al. (2014). runPythonAnalysis processes MDSC citation counts via pandas for trends (e.g., 2000+ citations post-2014), with GRADE grading assigning A-level evidence to Bronte nomenclature standards.

Synthesize & Write

Synthesis Agent detects gaps like 'PMN-MDSC hypoxia targeting' via contradiction flagging across Binnewies et al. (2018) and Kumar et al. (2016), then Writing Agent uses latexEditText for figure captions and latexSyncCitations to integrate 10 references. exportMermaid generates MDSC-T cell suppression pathway diagrams for reviews.

Use Cases

"Analyze MDSC suppression data from 5 key papers with statistics."

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas correlation of arginase levels vs T cell inhibition from Gabrilovich 2017, Bronte 2016) → matplotlib survival plots.

"Draft LaTeX review section on MDSC nomenclature."

Research Agent → citationGraph (Bronte 2016) → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → PDF with 20 citations.

"Find code for MDSC flow cytometry analysis."

Research Agent → paperExtractUrls (Italian et al. 2014) → Code Discovery → paperFindGithubRepo → githubRepoInspect → R scripts for M1/M2 gating.

Automated Workflows

Deep Research workflow scans 50+ MDSC papers via searchPapers, structures suppression mechanisms report with GRADE scores from Bronte et al. (2016) and Gabrilovich (2017). DeepScan applies 7-step CoVe to verify PD-L1 hypoxia claims (Noman et al., 2014), checkpointing against Deng et al. (2014). Theorizer generates hypotheses on MDSC-irradiation combos from citationGraph links.

Try Doxa for Myeloid-Derived Suppressor Cells in Cancer Research

Frequently Asked Questions

What defines MDSC subsets?

Bronte et al. (2016) standardize M-MDSC as CD14+HLA-DRlow/- and PMN-MDSC as CD15+CD66b+ in humans, with mouse equivalents Ly6G+Ly6Clow and Ly6C+Ly6G-.

What are main MDSC suppression methods?

MDSCs suppress via arginase-1 depletion of L-arginine, ROS generation, and NO production, blocking T cell proliferation (Gabrilovich, 2017). Hypoxia enhances PD-L1 expression on MDSCs (Noman et al., 2014).

What are key MDSC papers?

Bronte et al. (2016, 2630 citations) sets nomenclature; Gabrilovich (2017, 1801 citations) reviews mechanisms; Binnewies et al. (2018, 5583 citations) contextualizes in TIME.

What open problems exist for MDSCs?

Heterogeneous markers hinder clinical targeting; optimal combo therapies with checkpoint inhibitors need validation (Binnewies et al., 2018). MDSC plasticity between M1/M2 states remains unclear (Italiani and Boraschi, 2014).